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Background/introduction
Gliomas represent the most common and devastating
primary CNS tumor. While surgical resection is the
mainstay of treatment, treating physicians are seeking a
safer and more effective treatment modality that is non-
invasive, deep-penetrating, and less prone to infection
and damage to surrounding tissues. Photodynamic ther-
apy, utilizing a photosensitizing agent with laser light,
while effective in a variety of solid tissue tumors, has
not proven to be especially advantageous in the treat-
ment of gliomas, due to the poor penetration of the
light. Sonodynamic therapy has been explored as an
alternative to PDT. Sensitizers such as 5-aminolevulinic
acid (5-ALA) and indocyanine green (IcG) have been
shown to be preferentially taken up by glioma cells.
Low-intensity ultrasound waves can provide enough
energy to activate sensitizing agents and induce apopto-
sis, without the collateral damage to surrounding tissues
seen with laser light in PDT. The aim of this initial
study is to determine whether the sonosensitizers 5-
ALA and IcG can be effectively delivered to, and
detected in, the subcutaneous C6 glioma rat model.
Methods
A total of 12 rats were inoculated with the C6 rat
glioma cell line for use in this initial study. The rats
were then split into three groups: 4 rats were treated
with 100 mg/kg of intravenous 5-ALA, 4 rats were trea-
ted with 150 mg/mL of intravenous IcG, and 4 rats
were used as a control. Rats given 5-ALA were eutha-
nized 2 to 4 hours later. Tumors were then harvested
for fluorescent spectroscopy study. In rats which were
given IcG, we used in vivo imaging system to visualize
the fluorescence intensity of the tumor as compared
with the adjacent normal tissues.
Results and conclusions
Tumor assays for all 8 of the experimental rats demon-
strated uptake of the sensitizing agents. None of the
assays for the control rats were positive. Our results
confirm that 5-ALA and IcG were enriched in the sub-
cutaneous C6 glioma in rats via the fluorescence spec-
troscopy or in vivo imaging. Future steps will include
another proof-of-concept study to assess the ability of
low-intensity ultrasound to cause hyperthermia-induced
apoptosis in C6 gliomas via activation of 5-ALA and
IcG. A larger study would then be needed compare the
effectiveness of these sonosensitizers, and further opti-
mize ultrasound parameters. Ultimately we would like
to move this work towards a clinical trial.
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